Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Dec 9, 2025

Jim Lang Elected to Halozyme's Board of Directors

SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:  HALO ) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics.

PRNewsWire • Dec 8, 2025

The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.

Halozyme Therapeutics is a leader in the subcutaneous drug delivery niche, generating gobs of free cash flow. The company faces patent cliffs ahead for its core products and is actively trying to diversify its offerings.

The Motley Fool • Dec 6, 2025

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany. The Munich Regional Court's 7th Civil Division found that there is imminent infringement for Keytruda SC in Germany regarding one of Halozyme's MDASE™ patents in Europe, European Patent No.

PRNewsWire • Dec 4, 2025

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.

WSJ • Dec 4, 2025

Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 3, 2025

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 2, 2025

What Makes Halozyme Therapeutics (HALO) a New Buy Stock

Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Dec 1, 2025

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Nov 27, 2025

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference. The presentation is scheduled for Tuesday, December 2 at 10:20am PT / 1:20pm ET.

PRNewsWire • Nov 25, 2025